Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk trial with next-gen diabetes drug shows 15.7% weight loss but shares fall
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
Why Novo Nordisk Stock Is Falling Today
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...
Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
The Zacks Analyst Blog Novo Nordisk, The Coca-Cola, Wells Fargo and Star Group
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Novo Nordisk's Ozempic successor disappointed Wall Street again
Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...
Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.
STAT1d
Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...
Hikma looks to launch generic versions of Novo Nordisk diabetes drugs, FT says
Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents ...
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
Novo Nordisk shares fall on latest trial results for new obesity drug
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...